These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 28362269)

  • 1. Daclatasvir plasma concentration assessment in HIV-HCV-coinfected real-life patients.
    Taton A; Colson P; Dhiver C; Ruiz JM; Bregigeon S; Tomei C; Ressiot E; Menard A; Poizot-Martin I; Ravaux I; Lacarelle B; Solas C
    Antivir Ther; 2017; 22(8):731-733. PubMed ID: 28362269
    [No Abstract]   [Full Text] [Related]  

  • 2. Daclatasvir plus sofosbuvir, with or without ribavirin, in real-world patients with HIV-HCV coinfection and advanced liver disease.
    Rockstroh JK; Ingiliz P; Petersen J; Peck-Radosavljevic M; Welzel TM; Van der Valk M; Zhao Y; Jimenez-Exposito MJ; Zeuzem S
    Antivir Ther; 2017; 22(3):225-236. PubMed ID: 27845298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of Daclatasvir in HCV/HIV-Coinfected Patients in a Real-Life Setting.
    Bonora S; Puoti M
    AIDS Rev; 2017; 19(1):24-34. PubMed ID: 28182611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High Cure Rate With 24 Weeks of Daclatasvir-Based Quadruple Therapy in Treatment-Experienced, Null-Responder Patients With HIV/Hepatitis C Virus Genotype 1/4 Coinfection: The ANRS HC30 QUADRIH Study.
    Piroth L; Paniez H; Taburet AM; Vincent C; Rosenthal E; Lacombe K; Billaud E; Rey D; Zucman D; Bailly F; Bronowicki JP; Simony M; Diallo A; Izopet J; Aboulker JP; Meyer L; Molina JM;
    Clin Infect Dis; 2015 Sep; 61(5):817-25. PubMed ID: 25977266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study.
    Sulkowski MS; Fessel WJ; Lazzarin A; Berenguer J; Zakharova N; Cheinquer H; Côté P; Dieterich D; Gadano A; Matthews G; Molina JM; Moreno C; Pineda JA; Pulido F; Rivero A; Rockstroh J; Hernandez D; McPhee F; Eley T; Liu Z; Mendez P; Hughes E; Noviello S; Ackerman P
    Hepatol Int; 2017 Mar; 11(2):188-198. PubMed ID: 28210927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High serum HCV RNA in chronic hepatitis C patients coinfected with HIV despite successful antiretroviral therapy.
    Barreiro P; Labarga P; de Mendoza C; Benítez-Gutiérrez L; Fernandez-Montero JV; Peña JM; Soriano V
    Antivir Ther; 2016; 21(6):489-494. PubMed ID: 26887981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Editorial commentary: Management of hepatitis C Virus in HIV-infected patients in the era of direct-acting antivirals.
    Zeremski M; Martinez AD; Talal AH
    Clin Infect Dis; 2014 Mar; 58(6):880-2. PubMed ID: 24336913
    [No Abstract]   [Full Text] [Related]  

  • 8. Direct-acting antiviral treatment against hepatitis C virus infection in HIV-Infected patients - "En route for eradication"?
    Pradat P; Pugliese P; Poizot-Martin I; Valantin MA; Cuzin L; Reynes J; Billaud E; Huleux T; Bani-Sadr F; Rey D; Frésard A; Jacomet C; Duvivier C; Cheret A; Hustache-Mathieu L; Hoen B; Cabié A; Cotte L;
    J Infect; 2017 Sep; 75(3):234-241. PubMed ID: 28579302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of genotype 1 HCV infection in the HIV coinfected patient in 2014.
    Chastain CA; Naggie S
    Curr HIV/AIDS Rep; 2013 Dec; 10(4):408-19. PubMed ID: 24272069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C Virus Elimination in the Human Immunodeficiency Virus-Coinfected Population: Leveraging the Existing Human Immunodeficiency Virus Infrastructure.
    Clement ME; Collins LF; Wilder JM; Mugavero M; Barker T; Naggie S
    Infect Dis Clin North Am; 2018 Jun; 32(2):407-423. PubMed ID: 29778263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real life experience in treatment of HIV-1/HCV-coinfected patients with pegylated interferon alpha and ribavirin: predictors of SVR.
    Bruno G; Fasano M; Saracino A; Volpe A; Bartolomeo N; Ladisa N; Maggi P; Monno L; Angarano G
    New Microbiol; 2015 Jan; 38(1):21-7. PubMed ID: 25742144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daclatasvir and Sofosbuvir Versus Sofosbuvir and Ribavirin in Patients with Chronic Hepatitis C Coinfected with HIV: A Matching-adjusted Indirect Comparison.
    Swallow E; Song J; Yuan Y; Kalsekar A; Kelley C; Peeples M; Mu F; Ackerman P; Signorovitch J
    Clin Ther; 2016 Feb; 38(2):404-12. PubMed ID: 26839044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment of three patients with human immunodeficiency virus and hepatitis C virus genotype 1b co-infection by daclatasvir plus asunaprevir.
    Hirashima N; Iwase H; Shimada M; Ryuge N; Imamura J; Ikeda H; Tanaka Y; Matsumoto N; Okuse C; Itoh F; Yokomaku Y; Watanabe T
    Clin J Gastroenterol; 2017 Feb; 10(1):41-46. PubMed ID: 27766544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis.
    Simmons B; Saleem J; Hill A; Riley RD; Cooke GS
    Clin Infect Dis; 2016 Mar; 62(6):683-694. PubMed ID: 26787172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rates and predictors of response to anti-viral treatment for hepatitis C virus in HIV/HCV co-infection in a nationwide study of 619 patients.
    Ioannou GN; Scott JD; Yang Y; Green PK; Beste LA
    Aliment Pharmacol Ther; 2013 Dec; 38(11-12):1373-84. PubMed ID: 24127691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Efficacy of Pegylated Interferon Lambda, Ribavirin, and Daclatasvir in HCV and HIV-Coinfected Patients.
    Nelson M; Rubio R; Lazzarin A; Romanova S; Luetkemeyer A; Conway B; Molina JM; Xu D; Srinivasan S; Portsmouth S
    J Interferon Cytokine Res; 2017 Mar; 37(3):103-111. PubMed ID: 28282271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitation of hepatitis C virus RNA in peripheral blood mononuclear cells in HCV-monoinfection and HIV/HCV-coinfection.
    Chary A; Winters MA; Eisen R; Knight TH; Asmuth DM; Holodniy M
    J Med Virol; 2012 Mar; 84(3):431-7. PubMed ID: 22246828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of HIV infection in patients infected with chronic HCV (genotypes 1a and 3a): virological and clinical changes.
    Behzadpour D; Ahmadi Vasmehjani A; Mousavi Nasab SD; Ahmadi NA; Baharlou R
    Pathog Glob Health; 2016; 110(7-8):310-315. PubMed ID: 27830997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HCV viral load at baseline and at week 4 of telaprevir/boceprevir based triple therapies are associated with virological outcome in HIV/hepatitis C co-infected patients.
    Salmon D; Bani-Sadr F; Gilbert C; Rosenthal E; Valantin MA; Simon A; Neau D; Morlat P; Loko MA; Wittkop L; Dabis F;
    J Clin Virol; 2015 Dec; 73():32-35. PubMed ID: 26528903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of direct antiviral agents in a cohort of cirrhotic HCV/HIV-coinfected patients.
    Navarro J; Laguno M; Vilchez HH; Guardiola JM; Carrion JA; Force L; Cairó M; Cifuentes C; Vilaró J; Cucurull J; Marco A; Roget M; Erice E; Crespo M;
    J Antimicrob Chemother; 2017 Oct; 72(10):2850-2856. PubMed ID: 29091196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.